Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 182

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Drugs Repurposed as Antiferroptosis Agents Suppress Organ Damage, Including AKI, by Functioning as Lipid Peroxyl Radical Scavengers

Open access
Mishima, Eikan, Sato, Emiko, Ito, Junya, Yamada, Ken-ichi, Suzuki, Chitose, Oikawa, Yoshitsugu, Matsuhashi, Tetsuro, Kikuchi, Koichi, Toyohara, Takafumi, Suzuki, Takehiro, Ito, Sadayoshi, Nakagawa, Kiyotaka, Abe, Takaaki · 2020 · Journal of the American Society of Nephrology

Abstract

Significance Statement: Ferroptosis, cell death mediated by free radical reactions and driven by oxidative degradation of lipids, is a therapeutic target because of its role in organ injuries, including AKI. However, the ferroptosis-causing radicals targeted by ferroptosis suppressors have not been unequivocally identified. Certain cytochrome P450 substrate drugs are known to prevent lipid peroxidation via obscure mechanisms. The authors screened cytochrome P450 substrate drugs, identifying a diverse group of drugs with antiferroptotic properties, including promethazine and rifampicin. The antiferroptotic effect of these drugs was linked to their scavenging activity against lipid peroxyl radicals. Elevated lipid peroxyl radical levels were associated with ferroptosis onset, whereas radical scavenging by the drugs suppressed ferroptosis-related pathologic changes in different renal cell types and ameliorated organ injuries (including AKI) in mice, suggesting therapeutic potential for such repurposed drugs. Background: Ferroptosis, nonapoptotic cell death mediated by free radical reactions and driven by the oxidative degradation of lipids, is a therapeutic target because of its role in organ damage, including AKI. Ferroptosis-causing radicals that are targeted by ferroptosis suppressors have not been unequivocally identified. Because certain cytochrome P450 substrate drugs can prevent lipid peroxidation via obscure mechanisms, we evaluated their antiferroptotic potential and used them to identify ferroptosis-causing radicals. Methods: Using a cell-based assay, we screened cytochrome P450 substrate compounds to identify drugs with antiferroptotic activity and investigated the underlying mechanism. To evaluate radical-scavenging activity, we used electron paramagnetic resonance–spin trapping methods and a fluorescence probe for lipid radicals, NBD-Pen, that we had developed. We then assessed the therapeutic potency of these drugs in mouse models of cisplatin-induced AKI and LPS/galactosamine-induced liver injury. Results: We identified various US Food and Drug Administration–approved drugs and hormones that have antiferroptotic properties, including rifampicin, promethazine, omeprazole, indole-3-carbinol, carvedilol, propranolol, estradiol, and thyroid hormones. The antiferroptotic drug effects were closely associated with the scavenging of lipid peroxyl radicals but not significantly related to interactions with other radicals. The elevated lipid peroxyl radical levels were associated with ferroptosis onset, and known ferroptosis suppressors, such as ferrostatin-1, also functioned as lipid peroxyl radical scavengers. The drugs exerted antiferroptotic activities in various cell types, including tubules, podocytes, and renal fibroblasts. Moreover, in mice, the drugs ameliorated AKI and liver injury, with suppression of tissue lipid peroxidation and decreased cell death. Conclusions: Although elevated lipid peroxyl radical levels can trigger ferroptosis onset, some drugs that scavenge lipid peroxyl radicals can help control ferroptosis-related disorders, including AKI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1681/asn.2019060570

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 182

Metadata

Authors
Mishima, E., Sato, E., Ito, J., Yamada, K.-I., Suzuki, C., Oikawa, Y., Matsuhashi, T., Kikuchi, K., Toyohara, T., Suzuki, T., Ito, S., Nakagawa, K., & Abe, T.
Venue
Journal of the American Society of Nephrology
Published
2019-11-25
Volume
31
Issue
2
Pages
280-296
ISSN
  • 1046-6673 (ISSN-L)
  • 1533-3450
OpenAlex
W2990632313
Cited by
182
References
9
FWCI
9.22
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drugs Repurposed as Antiferroptosis Agents Suppress Organ Damage, Including AKI, by Functioning as Lipid Peroxyl Radical Scavengers. https://app.cochat.ai/papers/10.1681/asn.2019060570
The paper
Mishima, E., Sato, E., Ito, J., Yamada, K.-I., Suzuki, C., Oikawa, Y., Matsuhashi, T., Kikuchi, K., Toyohara, T., Suzuki, T., Ito, S., Nakagawa, K., & Abe, T. (2020). Drugs Repurposed as Antiferroptosis Agents Suppress Organ Damage, Including AKI, by Functioning as Lipid Peroxyl Radical Scavengers. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2019060570

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.